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Context is everything: extrinsic signalling
and gain-of-function p53 mutants
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Abstract
The TP53 genomic locus is a target of mutational events in at least half of cancers. Despite several decades of study, a
full consensus on the relevance of the acquisition of p53 gain-of-function missense mutants has not been reached.
Depending on cancer type, type of mutations and other unidentified factors, the relevance for tumour development
and progression of the oncogenic signalling directed by p53 mutants might significantly vary, leading to inconsistent
observations that have fuelled a long and fierce debate in the field. Here, we discuss how interaction with the
microenvironment and stressors might dictate the gain-of-function effects exerted by individual mutants. We report
evidence from the most recent literature in support of the context dependency of p53 mutant biology. This
perspective article aims to raise a discussion in the field on the relevance that context might have on p53 gain-of-
function mutants, assessing whether this should generally be considered a cell non-autonomous process.
Facts
● Mutant p53 GOF effects have been shown to vary in
different settings, potentially depending on cancer
types, experimental models and conditions.
● Reciprocal interaction between microenvironment
and mutant p53 GOF effects exists.
● Similarly to wt p53, mutant p53 proteins can
contribute to transduction of extrinsic signalling.
Questions
● What is the effective contribution of mutant p53
GOF effects to the cancer progression?
● How relevant is the microenvironmental context in
determining mutant p53 GOF effects?
● Can microenvironmental factors be targeted to
abolish mutant p53 GOF pro-oncogenic functions?
p53 protects cells from insults: why do cancers want to
lose this benefit?
p53 is a stress response protein1–5. Originally identified
as a major executor of the response to DNA damage, with
a more recent revision, p53 is considered a molecular hub
for the interactions between stressors (reactive oxygen
radicals [ROS], nutrient deprivation, hypoxia, telomere
erosion, etc.) and cellular biological responses5–12 (Fig. 1).
This view leads us to postulate that functional p53 pre-
vents cancer via multiple mechanisms; however, this
could also be more simplistically interpreted as the gen-
eral role of p53 in protecting the cell in response to
multiple types of stressors, which in most cases result in
the prevention of tumorigenesis. Occasionally, however,
efforts in defending the cell from potentially damaging
factors might cause p53 to protect cancer cells. Thus,
specific circumstances have emerged in which functional
p53 appears to help cancer cells cope with stressors, and
its contribution is beneficial for tumour progression13–16.
The ultimate goal of p53 function of protecting the cell
results in a tumour-suppressive function in the context of
normal cells and represents a prototypical example of
the complexity and context dependency of tumour-
suppressive mechanisms.
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p53 is, however, inactivated in at least 50% of human
cancers, indicating that cancer cells receive a selective
advantage in losing p53 function17. A hallmark of
p53-mutated cancer cells is the loss of control of genomic
integrity, which long ago led to the popular definition of
p53 as the “Guardian of the Genome”18. Multiple
mechanisms have been proposed, including the capability
of p53 to transcriptionally control the DNA repair
machinery19, to promote the death of highly damaged
cells20–22 and to prevent retrotransposons and mobile
elements from hopping across the genome23,24. The high
genomic instability of p53 mutant tumours is not essential
for the initiation of cancer; however, it strongly facilitates
progression of the disease, providing the plasticity
required to adapt to the constantly changing conditions
within the tumour ecosystem. Thus, the genetic plasticity
associated with p53 mutations is definitely an advantage
for cancer cells.
An additional critical aspect of the mutations in p53 is
the frequently observed protein products. Eighty percent
of p53 mutations are missense, leading to generation of
neomorphic proteins25,26, the function of which has been
associated with deregulation of a wide range of physio-
logical cellular signalling processes14 and interacting
partners, including its family members, p6327–29 and
p7330–34. These mechanisms are thought to support
tumorigenesis, leading to the postulation of the gain-of-
function (GOF) theory in p53 mutation26. The shift of p53
from the wild-type status to the mutant protein therefore
appears to turn p53 into an oncogene. This basic, con-
sistent and generally accepted consideration has, however,
not always found solid support in the experimental data.
Clear GOF phenotypes have been shown for many hot-
spot mutations, such as p53 R175H and R273H. Intro-
duction of p53 R175H and R273H into p53-null cells
promotes growth in in vitro soft-agar assays and in
injected nude mice. In contrast, genetically engineered
mouse models carrying mouse homologous mutations
(p53 R172H and R270H) did not show any alteration in
survival compared with p53-null mice.
Puzzling results have also been shown in myeloid malig-
nancies. GOF p53 R172H was seen to accelerate complex-
karyotype acute myeloid leukaemia in mouse models by
promoting cell fate plasticity through the pluripotency
factor FOXH135,36. However, a complementary approach
based on functional and transcriptional analyses of CRISPR-
Cas9-generated isogenic human leukaemia cell lines sug-
gested a selective advantage associated with a dominant
Fig. 1 p53 is a stress response protein. p53 represents a molecular hub in the interaction between extrinsic factors and the cellular biological
response. In response to stress, functional p53 exerts a protective role by promoting different mechanisms, which include apoptosis, DNA repair and
senescence, as well as rewiring of cellular metabolism, autophagy etc. In presence of p53 mutants, this physiological response can be altered leading
to aberrant cellular processes supporting tumorigenesis. This might underlie the GOF effect of p53 mutants.
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negative effect of p53 mutants but no evidence of any GOF.
This study also reported no evidence of GOF effects on the
clinical outcome of patients with myeloid malignancies37.
Whether this is different from solid tumours, where a pro-
invasion and pro-metastatic programme might benefit from
mutant p53 GOF, remains to be determined. However,
formal evidence for the existence of p53 mutant GOF
effects could be found in the dependency displayed by
cancers on sustained expression of p53 mutant proteins38.
Ablation of mutant p53 in allotransplanted, xeno-
transplanted and autochthonous mouse cancer models
impairs tumour growth, promoting cell death and tumour
regression or stagnation39–42. While these results allow
pharmacological targeting of the mechanisms leading to
p53 mutant stabilisation as an anticancer approach, at the
basic molecular level, they formally demonstrate that
expression of p53 mutant proteins is not equal to the loss of
the functional wild-type version. However, a general con-
sensus has not yet been achieved on the relevance of the
contribution of p53 GOF effects to tumorigenesis.
Recent evidence has indicated that GOF mutants
functionally interact with microenvironmental fac-
tors41,43. This is reflected in an influence of extrinsic
signalling on p53 mutant behaviour and on the ability of
the p53 mutant to modulate the response to extrinsic
factors. In light of the central role of functional (wt) p53 in
the response to cellular stress, a fundamental conserved
implication of the mutant proteins in the interaction with
microenvironment is not surprising (Fig. 1). The question
is therefore how much context matters in the oncogenic
properties of the GOF mutant and whether GOF effects
are dynamic biological processes that depend on the
specific microenvironmental conditions.
Do p53 mutants need to be activated?
p53 mutants are generally considered highly stable
proteins; however, this assumption is true only in the
context of tumour tissues44,45. Genetically modified mice
carrying p53 missense mutations indeed have very low
levels of protein in untransformed tissues46, and the sta-
bility of p53 mutants is heterogeneous within the tumour
mass in humans and mice. The mutant protein conserves
the wild-type intrinsically unstable nature associated with
a very tight regulation of proteasomal degradation, which
is mediated by MDM2 and CHIP47.
Stress-responsive systems of molecular chaperones,
involving Hsp70, Hsp90 and Hsp40/DNAJA1, counteract
p53 mutant degradation and modulates its conforma-
tional plasticity and stability48,49. The master transcription
factor heat-shock factor-1 (HSF1) transcriptionally pro-
motes the expression of Hsps, which in turn interact with
p53 mutants, inhibit the E3 ubiquitin ligase activity of
MDM2 and CHIP and induce the stability of p53 mutant
proteins. The mechanisms leading to the stabilisation of
p53 mutants are therefore influenced by extrinsic stres-
sors able to trigger the activation of HSF1. Similarly,
mechanical stimuli from the tumour tissues have also
been shown to result in p53 mutant stabilisation. Rho-A is
a sensor of extracellular matrix (ECM) stiffness. In
response to stiff a ECM, Rho-A activation and actin-
dependent mechanotransduction induce activation of
Hsp90 via the mechanosensitive HDAC6 deacetylase, thus
leading to stabilisation of mutant proteins50. Similar to
HSF1, Rho-A is also frequently hyperactive in tumour
tissues. Notably, Rho-A is regulated by mutant p53
activity itself. Activation of Rho-A is influenced by GEF-
H1 and RhoGDI, which are influenced by GOF p53
mutants, feeding a forward loop that results in further
stabilisation of the p53 mutant. Disruption of this loop
with zoledronic acid (ZA) and geranylgeranyl transferase
inhibitors (GGTIs), which inhibit the geranylgeranylation
of Rho-A required for its activation on the plasma
membrane, impairs p53 mutant stability26,43,51 (Fig. 2).
Cancer fibrosis has been associated with a high expression
level of the p53 mutant and represents a possible expla-
nation for its heterogeneous expression within the tumour
tissue52.
The functional interaction between Rho-A and mutant
p53 pulls the influence of cellular metabolism into the
equation of p53 mutant stability. Geranylgeranylation of
Rho-A requires activation of the mevalonate pathway, as
this supplies the substrates for the synthesis of the iso-
prenoid geranylgeranyl pyrophosphate50. This led to the
suggestion of repurposing statins as a potential strategy to
reduce p53 mutant stability48. The selective pharmaco-
logical effects of statins on p53 mutant breast cancer cells
have, however, also found alternative explanations. p53
mutant GOF effects have been reported in the context of
activation of the mevalonate pathway via deregulation of
SREBP2 transcriptional effects. Hence, p53 mutant breast
cancer cells have been suggested to be selectively vul-
nerable to statins, as p53 mutant-mediated promotion of
the mevalonate pathway facilitates invasiveness and dis-
ruption of mammary architecture in 3D culture53. Once
again, a feed-forward loop between the pathway regulat-
ing p53 mutant stability and the reciprocal influence of
the p53 mutant on the same pathway emerges, pointing
out the complexity of the interaction between cell-
autonomous and non-cell-autonomous factors at the
basis of these molecular networks.
These data indicate that, before being important in
defining p53 mutant function, the context is crucial for
determining whether the mutant protein is expressed or
not. Similar to the wild-type functional protein, p53
mutants respond to extrinsic signalling, which leads to
stabilisation of the protein. A convergence of mechanisms
conserved from the wild-type protein and newly acquired
by the mutant protein leads to “activation” of the p53 GOF
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mutant. Whether GOF effects are executed might therefore
depend on the extent of activation received by the p53
mutant protein.
p53 mutants instruct the microenvironment
The context dependency of oncogenic and oncosup-
pressive signalling has now clearly emerged. The simplistic
cell-autonomous model of the oncogenic effects mediated
by hyperactive mitogenic mutated proto-oncogenes has
been widely revised with the increasing complexity of the
oncogenic effects of mutant proteins and the contribution
of extrinsic signalling. Cellular fate appears to be dictated
by the integration of the genetic landscape and
microenvironmental cues.
In addition to the impact on protein stability, a stringent
relationship exists between p53 mutants and the micro-
environment; p53 mutants have emerged as a significant
contributor to shaping the microenvironmental conditions.
Central factors of the tumour microenvironment, such
as the ECM composition, appear to be influenced by
mutant p53 GOF. A cooperation between p53 mutants
and hypoxia-inducible factor-1 (HIF-1) determines the
expression of fundamental components of the basal
lamina, such as laminin-γ2 and collagen type VIIa1, in
hypoxic tumours41. The result of the cooperation between
the p53 mutant and HIF-1 is the generation of a pro-
tumorigenic microenvironment that facilitates the inva-
sion of lung cancer cells and the growth of xeno-
transplanted tumours41,54,55. Remarkably, the trigger of
this p53 mutant GOF requires hypoxia to initiate the HIF-
1-mediated response; thus, again, a reciprocal interaction
between extrinsic and intrinsic factors participates in the
cascade of events (Fig. 2).
GOF p53 mutants can also facilitate a pro-tumorigenic
microenvironment by promoting the secretion of IL-8 and
GRO-α by cancer cells. Similar to the p53 mutant/HIF-1
molecular model, p53 mutants appear to hijack the E2F2
transcriptional factor. The p53 mutant/E2F2 complex
controls the promoter of inhibitor of DNA binding 4 (ID4),
which binds and stabilise mRNAs of IL-8 and GRO-α.
Conditioned media from p53 mutant cells promote the
in vitro proliferation of endothelial cells, and p53 mutants
favour angiogenesis in vivo in xenotransplanted models56.
Consistently, vessel density correlates with the expression of
p53 missense mutations in human breast cancers57.
N-glycosylation of cellular surface proteins, such as
receptors and integrins, is also altered by p53 status.
Ectonucleoside triphosphate diphosphohydrolase 5
Fig. 2 p53 mutants interaction with extracellular matrix. ECM stiffness induces HDAC6/ Hsp90-dependent stabilisation of mutant p53 with a
molecular mechanism involving mevalonate pathway-dependent Rho-A geranylgeranylation. Mutant p53 in turn sustains mevalonate pathway
activity providing a forward loop, which facilitates its protein stabilisation. In addition to that, in hypoxic microenvironment, mutant p53 promotes
expression of ECM components, which then can trigger stabilisation of mutant p53.
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(ENTPD5) is a mutant p53 target gene involved in pro-
moting the folding of N-glycosylated membrane proteins
in the endoplasmic reticulum58. Cooperation between
mutant p53 and Sp1 facilitates transcriptional control of
ENTPD5, and this appears to mediate p53 mutant-
dependent growth, architectural tissue remodelling,
migration, invasion and lung colonisation as assessed in
tail vein-implantation mouse models58.
Evidence exists that p53 mutants can influence the
microenvironment. Simplification tends to indicate how
“mutants” direct the composition of the extracellular
milieu; however, it is reasonable to speculate that different
mutations will have different impacts on this process.
However, the large variety of mutations makes the reso-
lution of this issue very challenging (Fig. 1).
Conclusion: p53 mutants: one gene, many proteins in
many contexts
In this perspective, we suggest that p53 GOF is a non-cell-
autonomous phenomenon, which would make this gene
very peculiar if compared with other oncogenes/oncosup-
pressors, such as KRas59,60, Rb61,62 or Bcl-263–67. The p53
mutant can dictate instructions to the microenvironment,
which in turn are influenced by additional extrinsic factors
that direct signals on the cancer cells that are differentially
integrated based on the p53 mutational status (Fig. 3). Thus,
in the regulatory circle established between cancer cells and
the microenvironment, p53 mutants represent a molecular
hub determining the outcome.
It is remarkable that a significant fraction of work on
p53 GOF is performed in in vitro systems or in xeno-
transplanted models. Compelling evidence indicates that
plastic dishes provide altered extracellular matrix inter-
actions to cancer cells, influencing the stability of p53
mutants and consequentially providing artificial respon-
ses51. The limited ability of in vitro and xenotransplanted
models to recapitulate the natural cancer microenviron-
ment might represent a particular concern in the inter-
pretation of the data on p53 GOF. The addiction that
cancer cells develop to p53 mutations is a specific relevant
aspect in this context. While strong support for the
existence and relevance of p53 GOF comes from evidence
that in vivo tumours are dependent on p53 expression, no
evidence exists of the reproducibility of this effect in vitro.
This questions not only the work done to dissect the
mechanisms underlying p53 GOF but also the utility of
in vitro models for developing therapeutic approaches to
target p53 mutant stability.
It appears optimistic to envisage general major
mechanisms responsible for p53 GOF, but it is possibly
also very optimistic to envisage the existence of p53
mutant of similar mechanisms in different contexts.
This raises complexity in the study of p53 GOF, but
even more, it presents challenges in identifying strate-
gies to target this gene with general approaches in
cancer patients. While a massive effort in drug devel-
opment against p53 mutant tumours has been invested
in the two past decades, the outcome is very soon
expected to be delivered. This should also help in
understanding how feasible the approach is and direct
efforts for future investments68.
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Fig. 3 Integration between extrinsic stressors and p53 status
determines cellular fate. Mutant p53 function is influenced by
extrinsic stressors and in turn can shape the tumour
microenvironments. Integration of extinct stressors and mutant p53-
depedent signalling can determine cellular fate. Thus, mutant p53
GOF might be a context dependent process.
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